骨の近く: 組織特異のチェックポイント 免疫療法回避
1Department of Medicine of University of Verona, Policlinico GB Rossi, Piazzale L.A. Scuro 10, 37134 Verona, Italy.
Cell
|November 16, 2019
まとめ
免疫チェックポイント療法への抵抗は,がんが広がる場所に依存します. 骨転移は 治療の効果を阻害する 敵対的な環境を作り出します
科学分野:
- 腫瘍学
- 免疫学
- 癌 の 転移
背景:
- 免疫チェックポイント阻害剤 (ICI) は 癌治療に革命をもたらしました
- ICIに対する耐性は重要な臨床的課題です.
- 腫瘍の微小環境の異質性は,治療反応に影響する.
研究 の 目的:
- 免疫チェックポイント療法に対する転移部位の影響を調査する.
- 治療抵抗性における骨の微環境の役割を特徴づける
主な方法:
- 主要腫瘍と骨転移の分析
- 異なる転移部位における免疫細胞の浸透と機能の評価
- 骨転移のニッチを研究するための in vivo および in vitro モデル.
主要な成果:
- 転移の位置がICI耐性を大きく影響する.
- 骨転移は特に 敵対的な微生物環境を作り出します
- 骨内の特定の細胞および分子因子は 抵抗性を促進します
結論:
- 転移部位は免疫チェックポイント療法の有効性を決定する重要な要因です.
- 骨の微小環境をターゲットにすることで 抵抗を克服できます
- 将来の戦略は,治療の設計における転移のニッチを考慮する必要があります.
関連する概念動画
Cell-mediated Immune Responses
83.1K
Overview
83.1K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cytotoxic T Cells-mediated Immune Response
6.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.4K
Adaptive Mechanisms in Cancer Cells
6.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K
Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K


